Past issues are only available to subscribers. If you are not a member, click here to join.

ISSUE 2 – JAN. 10, 2014PDF

Orlando Hospital Severs MD Anderson Ties,
Forming Center with University of Florida

On Jan. 30, somebody will have to climb to the top of Orlando Health’s 10-story Charles Lewis Pavilion to cover up—or start removing—the backlit letters that, with a halo effect created by LED lights, broadcast the health system’s affiliation with MD Anderson Cancer Center.

The name of the distant, venerable cancer center will vanish from Orlando’s skyline. The distinctive red swoosh that symbolically negates the word “cancer” will be gone also.

photoOrlando Health President Mark Roh:
We Opted For a Florida-Centric Strategy

Orlando Health is choosing a partnership over an affiliation, said Mark Roh, president of the Florida cancer center that’s ending its relationship with MD Anderson Cancer Center. Instead, Roh’s hospital is joining the University of Florida to create the UF Health Cancer Center at Orlando Health.

photoLudwig Cancer Research Donates
$540 Million to Six Centers

Ludwig Cancer Research donated a total of $540 million to six of its centers, located at institutions across the country.

photoAVEO’s Tivozanib Fails In Colorectal Cancer

AVEO Oncology said that data from a planned interim analysis of the phase II BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population. 

photoTask Force Issues Guideline On LDCT Lung Screening

The U.S. Preventive Services Task Force released its final recommendation statement on screening for lung cancer with low-dose computed tomography.

photoACS: Decline in Death Rates Saved
Over 1.3 Million Lives

Declines in death rates over past two decades have added up to a 20 percent drop in the overall risk of dying from cancer, according to the American Cancer Society’s annual statistics report.

photoIn Brief

  • Gary Lyman to co-direct Fred Hutch outcomes research

  • Gary Schwartz named chief of NewYork-Presbyterian/Columbia University Medical Center Division of Hematology/Oncology 

  • Richard Gannotta named president of Northwestern Memorial Hospital

  • NCI Director Harold Varmus wins Medal of Honour from International Agency for Research on Cancer


FDA News

  • Accelerated Approval granted for Mekinist-Taflinar combination

  • European Commission amends Erbitux label

  • FDA and EMA launch joint initiative for generics inspections

20140110 - Jan. 10, 2014
ISSUE 1 – JAN. 3, 2014PDF

Who Makes This Drug?
Secretive Contract Manufacturing Arrangements Complicate Solutions to Shortages of Generics

By Rena M. Conti
The closing of Ben Venue Laboratories, a company that produces a large share of generic drugs used by America’s oncologists, brings into focus a little-understood business practice that exacerbates the problem of drug shortages and shows why the industry and federal regulators have been unable to resolve them.

photoReport to the Nation: Death Rates Continue To Decline Across All Major Disease Sites

Death rates continued to decline for all cancers combined for men and women of all major racial and ethnic groups and for most major cancer sites, according to the Annual Report to the Nation on the Status of Cancer. Rates for both sexes combined decreased by 1.5 percent per year from 2001 through 2010.

photoAn Appreciation: Janet Rowley, “Translational Research Pioneer”

Janet Rowley, a pioneer in connecting the development of cancer with genetic abnormalities, died from complications of ovarian cancer on Dec. 17 at her home. She was 88.

photoIn Brief

  • Julie Vose Elected President of ASCO
  • 2014 Breakthrough Prize Winners Announced
  • Andrea Sloan, Prominent Ovarian Cancer Patient Dies
20140103 - Jan. 2, 2014
ISSUE 46 – DEC. 13, 2013PDF

CPRIT Official Indicted for Skipping Peer Review

By Paul Goldberg
A grand jury in Travis County, Texas, indicted a former official of the Cancer Prevention and Research Institute of Texas for bypassing peer review in awarding an $11 million grant to a Dallas-based company.

photoWhy I Don’t Want to Pay for Your Horoscope:
Reflections on FDA Warning to 23andMe

Guest Editorial by Jim Evans
There’s been much recent gnashing of teeth (at least within the narrow and rather insular world of do-it-yourself genomics) about the gall of the FDA in choosing to issue a warning letter to 23andMe, effectively shutting down marketing of their direct-to-consumer personal genomic profiling. And adding to 23andMe’s woes, a class action suit has been filed against them.

photoBipartisan Deal Eases Some Budget Cuts By Extending Sequestration Through 2023

By Matthew Bin Han Ong
The House of Representatives voted 332-94 to approve a two-year budget outline Dec. 12 that would cancel $63 billion in sequester cuts for 2014 and 2015—in exchange for extending sequestration through 2023.

photoIn Brief

  • Thomas Burke stepped down as executive vice president and physician-in-chief at MD Anderson Cancer Center
  • Edward Jackson named chair of the Department of Medical Physics at the University of Wisconsin School of Medicine and Public Health
  • David Chang appointed professor of plastic surgery at the University of Chicago School of Medicine
  • Steve Mackin named chief operating officer of Cancer Treatment Centers of America
20131217_4 - Dec. 17, 2013
ISSUE 45 – DEC. 6, 2013PDF

example

Wall Street Analyst Who Sounded Alarm
Over Prostate Cancer Drug Provenge In JNCI
Settles with SEC Over Shorting Dendreon Stock

The lead author of a paper that argued that the prostate cancer immunotherapy Provenge endangered lives of cancer patients has entered a settlement agreement with the Securities and Exchange Commission.

The agreement states that Marie Huber, an analyst at a hedge fund, had prepared and anonymously circulated a paper about Provenge (sipuleucel-T) at a time when her put options in Dendreon Inc., the drug’s sponsor, were about to expire.

photoNCI Urged to Boost Gastric Cancer Funding

A group of members of both chambers of Congress is urging NCI to increase funding for research in gastric cancers—the latest in a string of advocacy initiatives to carve out fiscal support for specific diseases.

photoIn Brief

  • Lenora Johnson to leave NCI Office of Communications

  • Adrienne Lang steps down as VP for executive operations at MD Anderson Cancer Center

  • Michael Foley selected to lead the Tri-Institutional Therapeutics Discovery Institute Inc.

  • Beti Thompson to present AACR Distinguished Lecture on Cancer Health Disparities

FDA News

  • Supplemental new drug application for Nexavar tablets (sorafenib) approved

  • 510(k) clearance granted to an estrogen receptor image analysis and digital read application for breast cancer

  • Aptima HPV 16 18/45 genotype assay approved

  • Priority Review granted to ramucirumab as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy

  • FDA and the European Medicines Agency grant orphan drug designation to IMAB362

20131217 - Dec. 17, 2013
Issue 44 – Nov. 22, 2013PDF

example

ASCO Vying for Big Role in Big Data

Conversation with The Cancer Letter: ASCO President Clifford Hudis

The American Society of Clinical Oncology is in the final stages of developing a request for proposals for its CancerLinQ system. The RFP is expected to be issued early in 2014.

photoBiospecimen Banks Program for NCTN

Moves Forward With Approval From BSA

As NCI digs out after the two-week shutdown of the federal government, its leadership has to contend with the prospect of another shutdown weeks away, which may kick in after the current continuing resolution expires Jan. 15, 2014.

photoPiotr Kulesza, 46, Pathologist At Northwestern,
ECOG-ACRIN, Dies in Fall After Group Meeting
Piotr Kulesza, a pathologist at Northwestern University Robert H. Lurie Cancer Center, who worked with the ECOG-ACRIN Cancer Research Group, died after a fall from a hotel balcony after attending the cooperative group’s semi-annual meeting. Kulesza was 46.
photo
In Brief
20131203_14 - Dec. 3, 2013
ISSUE 43 – NOV. 15, 2013PDF

example


A new kind of clinical trial that will assign patients to therapy based on molecular characteristics of their disease is being launched by a coalition of government agencies, pharmaceutical companies, and a non-government organization.

The effort, called the lung cancer “Master Protocol,” is a phase II and phase III trial that would test five drugs, assigning patients to therapy based on tumor biomarkers.

photoVarmus: “We Are Shrinking Everything” To Keep Grant Numbers Level During Cuts

As NCI digs out after the two-week shutdown of the federal government, its leadership has to contend with the prospect of another shutdown weeks away, which may kick in after the current continuing resolution expires Jan. 15, 2014.

photoFDA Grants Accelerated Approval to Imbruvica

FDA granted an accelerated approval to Imbruvica (ibrutinib) for mantle cell lymphoma patients who have received at least one prior therapy. 

Imbruvica was approved four months after submission of its New Drug Application. The agent is sponsored by Pharmacyclics Inc.

20131203_10 - Dec. 3, 2013
ISSUE 42 – NOV. 8, 2013PDF

example

Wicha to Leave Director’s Job at UMich

Conversation with The Cancer Letter: Max Wicha

After 27 years and six NCI cancer center support grants, Max Wicha announced he would step down as director of the University of Michigan Comprehensive Cancer Center.

“Frankly, my research is really going well now,” Wicha said in a Q&A with The Cancer Letter. “It’s in a very exciting phase in researching cancer stem cells. My lab has grown—and my work is now moving into the clinic, so I’m actually working with our clinical people to do clinical trials targeting cancer stem cells. 

“So the idea of five more years, or do I get to really focus on my research now? That was really the deciding factor. 

“So it’s time. Again, six core grants is quite a number.”

photo

More than 230,000 people—including 82 Texas state lawmakers—petitioned BioMarin Pharmaceutical Inc. to provide its investigational drug to an Austin attorney afflicted with stage IIIC ovarian cancer.

photoIn Brief

  • Lynne Penberthy named NCI DCCPS associate director for surveillance

  • Michele Bloch appointed chief of NCI Tobacco Control Research Branch

  • MD Anderson’s James Allison named 2013 Innovations Award winner in Bioscience by The Economist

  • European Commission approves Yervoy for first-line treatment of adult unresectable or metastatic melanoma

  • FDA approves generic Morphine Sulfate Injection

20131203_6 - Dec. 3, 2013
ISSUE 41 – NOV. 1, 2013PDF

example

Rosen Moves to City of Hope

Steven Rosen is leaving his job as director of Northwestern University Robert H. Lurie Cancer Center to become the center director, provost, and chief scientific officer at City of Hope National Medical Center.

The move is interesting in part because, after 25 years in the top job at Northwestern, Rosen is the second longest-serving director of a cancer center in the U.S. (Rosen’s friend Max Wicha, who became director of the University of Michigan Cancer Center 27 years ago, is the first.)

photo

Conversation with The Cancer Letter: Steven Rosen

Robert Stone, president and incoming CEO of City of Hope, described the evolution of the novel leadership structure at his institution.

While most directors of cancer centers have to fulfill a multitude of very different roles, City of Hope has redistributed these roles, creating the role of provost and chief scientific officer to shape and direct the scientific and educational activities at the institution.

The role encompasses all units of City of Hope: the Comprehensive Cancer Center, the Beckman Research Institute of City of Hope, a National Medical Center, a Medical Foundation, a graduate school for biological sciences, and nationwide philanthropy.

photoQuality of Care: ASCO Publishes “Top Five” Ways to Improve Cancer Care

The American Society of Clinical Oncology published its second list of five opportunities to improve the quality and value of cancer care in the Journal of Clinical Oncology.

photoCost of Care: Medicare Patients Charged More In Outpatient Care Settings

Patients receiving chemotherapy in hospital outpatient departments face up to 47 percent higher costs compared to patients treated in physician community cancer clinics, according to a report prepared by The Moran Company and released by The US Oncology Network and the Community Oncology Alliance.

photoIn Brief

  • Larry Kun Named Clinical Director at St. Jude

  • Paula Rieger, CEO of the Oncology Nursing Society, announces plans to retire

  • FDA Approves Gazyva in CLL, The Agency’s First Approval of a Breakthrough Therapy

  • FDA Requests Manufacturer Suspend Sales and Marketing of Iclusig

20131203 - Dec. 3, 2013
Page 21 of 21« First...12131415161718192021